Cambridge, Massachusetts-based Apnimed has submitted a New Drug Application (NDA) to the US FDA for AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg), seeking approval as an oral treatment for adults with obstructive sleep apnea across all severity levels. The FDA has accepted the filing and assigned a PDUFA target action date of February 28, 2027. If approved, AD109 would be the first oral pharmacological therapy indicated for OSA regardless of obesity status — a distinction that separates it from tirzepatide (Zepbound), the only currently approved pharmacological option, which is restricted to patients with comorbid obesity.
The OSA treatment landscape has been dominated by mechanical and surgical interventions for decades. Continuous positive airway pressure remains the standard of care for moderate-to-severe disease, but adherence is poor, with estimates suggesting 30–50% of patients cannot or will not sustain long-term use. Inspire Medical's implantable hypoglossal nerve stimulator offers an alternative for CPAP-intolerant patients but requires surgical implantation. Eli Lilly's Zepbound received FDA approval in December 2024 for moderate-to-severe OSA, though its mechanism — weight reduction via GIP/GLP-1 receptor agonism — limits eligibility to obese patients and does not directly address the neuromuscular dysfunction underlying airway collapse.
AD109 combines aroxybutynin, a novel antimuscarinic, with atomoxetine, a selective norepinephrine reuptake inhibitor. During sleep, reduced noradrenergic activity and excess cholinergic inhibition diminish upper airway dilator muscle tone, causing repetitive airway collapse. Aroxybutynin reduces inhibitory cholinergic signaling to those muscles while atomoxetine increases noradrenergic drive, together restoring neuromuscular tone and reducing apnea events. The combination is taken as a once-daily oral pill at bedtime.
The NDA is supported by two Phase III randomized, double-blind, placebo-controlled trials — SynAIRgy and LunAIRo — enrolling adults with mild, moderate, and severe OSA. Both trials reported statistically significant reductions in apnea-hypopnea index, the primary endpoint, along with improvements in hypoxic burden and oxygen desaturation index. Apnimed has not publicly disclosed specific numerical results from either trial. The most commonly reported adverse events were dry mouth, insomnia, and nausea, consistent with the pharmacological profiles of both components and with findings from earlier-stage studies.